(Q22241472)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23039386%20AND%20SRC:MED&resulttype=core&format=json

9 March 2020

title

Neurodegeneration in multiple sclerosis: novel treatment strategies (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23039386%20AND%20SRC:MED&resulttype=core&format=json

9 March 2020

0 references

3

Frauke Zipp

Frauke

Zipp

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23039386%20AND%20SRC:MED&resulttype=core&format=json

9 March 2020

2

Volker Siffrin

Volker

Siffrin

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23039386%20AND%20SRC:MED&resulttype=core&format=json

9 March 2020

1

Felix Luessi

Felix

Luessi

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23039386%20AND%20SRC:MED&resulttype=core&format=json

9 March 2020

language of work or name

English

0 references

publication date

1 September 2012

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23039386%20AND%20SRC:MED&resulttype=core&format=json

Expert Review of Neurotherapeutics: a key contribution to decision making in the treatment of neurologic and neuropsychiatric disorders

9 March 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23039386%20AND%20SRC:MED&resulttype=core&format=json

9 March 2020

volume

12

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23039386%20AND%20SRC:MED&resulttype=core&format=json

9 March 2020

page(s)

1061-76; quiz 1077

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23039386%20AND%20SRC:MED&resulttype=core&format=json

9 March 2020

issue

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23039386%20AND%20SRC:MED&resulttype=core&format=json

9 March 2020

1 reference

Key issues in the diagnosis and treatment of multiple sclerosis. An overview

21 January 2018

1 reference

Defining the clinical course of multiple sclerosis: Results of an international survey

21 January 2018

1 reference

Multiple sclerosis - candidate mechanisms underlying CNS atrophy

21 January 2018

1 reference

Axonal pathology in multiple sclerosis. A historical note.

21 January 2018

1 reference

Indirect evidence for early widespread gray matter involvement in relapsing-remitting multiple sclerosis.

21 January 2018

1 reference

Axonal damage in acute multiple sclerosis lesions.

21 January 2018

1 reference

Axonal transection in the lesions of multiple sclerosis

21 January 2018

1 reference

Acute axonal damage in multiple sclerosis is most extensive in early disease stages and decreases over time.

21 January 2018

1 reference

Intracortical multiple sclerosis lesions are not associated with increased lymphocyte infiltration.

21 January 2018

1 reference

Cortical demyelination and diffuse white matter injury in multiple sclerosis.

21 January 2018

1 reference

Axonal loss in normal-appearing white matter in a patient with acute MS.

21 January 2018

1 reference

Evidence of axonal damage in the early stages of multiple sclerosis and its relevance to disability

21 January 2018

1 reference

Imaging outcomes for neuroprotection and repair in multiple sclerosis trials

21 January 2018

1 reference

A new window in multiple sclerosis pathology: non-conventional quantitative magnetic resonance imaging outcomes

21 January 2018

1 reference

Time domain and spectral domain optical coherence tomography in multiple sclerosis: a comparative cross-sectional study

21 January 2018

1 reference

Mechanisms of action of disease-modifying agents and brain volume changes in multiple sclerosis

21 January 2018

1 reference

Brain atrophy in multiple sclerosis: what we know and would like to know

21 January 2018

1 reference

Normalized accurate measurement of longitudinal brain change.

21 January 2018

1 reference

Eight-year follow-up study of brain atrophy in patients with MS.

21 January 2018

1 reference

The place of conventional MRI and newly emerging MRI techniques in monitoring different aspects of treatment outcome

21 January 2018

1 reference

Non-conventional MRI techniques for measuring neuroprotection, repair and plasticity in multiple sclerosis

21 January 2018

1 reference

MR spectroscopy in multiple sclerosis.

21 January 2018

1 reference

Axonal damage correlates with disability in patients with relapsing-remitting multiple sclerosis. Results of a longitudinal magnetic resonance spectroscopy study.

21 January 2018

1 reference

Magnetization transfer magnetic resonance imaging in the assessment of neurological diseases

21 January 2018

1 reference

Magnetization transfer ratio and myelin in postmortem multiple sclerosis brain

21 January 2018

1 reference

Retinal nerve fiber layer axonal loss and visual dysfunction in optic neuritis

21 January 2018

1 reference

Relation of visual function to retinal nerve fiber layer thickness in multiple sclerosis.

21 January 2018

1 reference

Optical coherence tomography and disease subtype in multiple sclerosis.

21 January 2018

1 reference

Retinal nerve fiber layer is associated with brain atrophy in multiple sclerosis

21 January 2018

1 reference

High resolution spectral domain optical coherence tomography (SD-OCT) in multiple sclerosis: the first follow up study over two years.

21 January 2018

1 reference

Genetic risk and a primary role for cell-mediated immune mechanisms in multiple sclerosis

21 January 2018

1 reference

Virtual hypoxia and chronic necrosis of demyelinated axons in multiple sclerosis

21 January 2018

1 reference

Resting microglial cells are highly dynamic surveillants of brain parenchyma in vivo

21 January 2018

1 reference

Microglial recruitment, activation, and proliferation in response to primary demyelination

21 January 2018

1 reference

Evidence for synaptic stripping by cortical microglia.

21 January 2018

1 reference

Microglial physiology: unique stimuli, specialized responses

21 January 2018

1 reference

Lower motor neuron loss in multiple sclerosis and experimental autoimmune encephalomyelitis.

21 January 2018

1 reference

Biotechnological agents for the immunotherapy of multiple sclerosis. Principles, problems and perspectives

21 January 2018

1 reference

Experimental autoimmune encephalomyelitis repressed by microglial paralysis.

21 January 2018

1 reference

Clonal expansions of CD8(+) T cells dominate the T cell infiltrate in active multiple sclerosis lesions as shown by micromanipulation and single cell polymerase chain reaction

21 January 2018

1 reference

Oligoclonal expansion of memory CD8+ T cells in cerebrospinal fluid from multiple sclerosis patients

21 January 2018

1 reference

Analysis of regulatory CD8 T cells in Qa-1-deficient mice

21 January 2018

1 reference

Regulation of activated CD4+ T cells by NK cells via the Qa-1-NKG2A inhibitory pathway.

21 January 2018

1 reference

Regulatory CD8+ T cells fine-tune the myelin basic protein-reactive T cell receptor V beta repertoire during experimental autoimmune encephalomyelitis

21 January 2018

1 reference

Cytotoxic CD8+ T cell-neuron interactions: perforin-dependent electrical silencing precedes but is not causally linked to neuronal cell death.

21 January 2018

1 reference

MHC class I-restricted killing of neurons by virus-specific CD8+ T lymphocytes is effected through the Fas/FasL, but not the perforin pathway,.

21 January 2018

1 reference

Transection of major histocompatibility complex class I-induced neurites by cytotoxic T lymphocytes

21 January 2018

1 reference

Mechanisms of axonal degeneration in EAE--lessons from CNTF and MHC I knockout mice

21 January 2018

1 reference

Suppression of experimentally induced autoimmune encephalomyelitis by cytolytic T-T cell interactions.

21 January 2018

1 reference

Repeated subcutaneous injections of IL12/23 p40 neutralising antibody, ustekinumab, in patients with relapsing-remitting multiple sclerosis: a phase II, double-blind, placebo-controlled, randomised, dose-ranging study

21 January 2018

1 reference

Mapping multiple sclerosis susceptibility to the HLA-DR locus in African Americans

21 January 2018

1 reference

HLA-DQ8 (DQB1*0302)-restricted Th17 cells exacerbate experimental autoimmune encephalomyelitis in HLA-DR3-transgenic mice.

21 January 2018

1 reference

Direct impact of T cells on neurons revealed by two-photon microscopy in living brain tissue.

21 January 2018

1 reference

Neuronal damage in autoimmune neuroinflammation mediated by the death ligand TRAIL.

21 January 2018

1 reference

In vivo imaging of partially reversible th17 cell-induced neuronal dysfunction in the course of encephalomyelitis

21 January 2018

1 reference

Use of proton magnetic resonance spectroscopy for monitoring disease progression in multiple sclerosis.

21 January 2018

1 reference

Mitochondrial dysfunction as a cause of axonal degeneration in multiple sclerosis patients.

21 January 2018

1 reference

Axonal degeneration in multiple sclerosis: the mitochondrial hypothesis

21 January 2018

1 reference

Mitochondrial defects in acute multiple sclerosis lesions

21 January 2018

1 reference

Mitochondrial changes within axons in multiple sclerosis

21 January 2018

1 reference

Heterogeneity of multiple sclerosis lesions: implications for the pathogenesis of demyelination

21 January 2018

1 reference

Histopathology and serial, multimodal magnetic resonance imaging in a multiple sclerosis variant.

21 January 2018

1 reference

Molecular antagonism and plasticity of regulatory and inflammatory T cell programs

21 January 2018

1 reference

Na+-dependent sources of intra-axonal Ca2+ release in rat optic nerve during in vitro chemical ischemia.

21 January 2018

1 reference

Role of extracellular calcium in anoxic injury of mammalian central white matter

21 January 2018

1 reference

Calpain-dependent neurofilament breakdown in anoxic and ischemic rat central axons.

21 January 2018

1 reference

Axon-glial signaling and the glial support of axon function

21 January 2018

1 reference

Multiple sclerosis: an immune or neurodegenerative disorder?

21 January 2018

1 reference

A role for oligodendrocyte-derived IGF-1 in trophic support of cortical neurons.

21 January 2018

1 reference

Axonal swellings and degeneration in mice lacking the major proteolipid of myelin.

21 January 2018

1 reference

Copolymer 1 induces T cells of the T helper type 2 that crossreact with myelin basic protein and suppress experimental autoimmune encephalomyelitis

21 January 2018

1 reference

Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind placebo-controlled trial. The Copolymer 1 Multiple Sclerosis Study Group

21 January 2018

1 reference

Differential mechanisms of action of interferon-beta and glatiramer aetate in MS.

21 January 2018

1 reference

Interferon-beta and neuroprotection in multiple sclerosis--facts, hopes and phantasies

21 January 2018

1 reference

Multiple sclerosis: comparison of copolymer-1- reactive T cell lines from treated and untreated subjects reveals cytokine shift from T helper 1 to T helper 2 cells

21 January 2018

1 reference

Mechanism of action of glatiramer acetate in multiple sclerosis and its potential for the development of new applications

21 January 2018

1 reference

Glatiramer acetate-specific T-helper 1- and 2-type cell lines produce BDNF: implications for multiple sclerosis therapy. Brain-derived neurotrophic factor

21 January 2018

1 reference

Glatiramer acetate reduces the proportion of new MS lesions evolving into "black holes".

21 January 2018

1 reference

Long-term study of brain 1H-MRS study in multiple sclerosis: effect of glatiramer acetate therapy on axonal metabolic function and feasibility of long-Term H-MRS monitoring in multiple sclerosis.

21 January 2018

1 reference

Interferon-beta inhibits mitogen induced astrocyte proliferation in vitro.

21 January 2018

1 reference

Effects of interferon beta-1b on black holes in multiple sclerosis over a 6-year period with monthly evaluations.

21 January 2018

1 reference

Sphingosine 1-phosphate and its receptors: an autocrine and paracrine network

21 January 2018

1 reference

Fingolimod (FTY720) enhances remyelination following demyelination of organotypic cerebellar slices.

21 January 2018

1 reference

A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis

21 January 2018

1 reference

Cladribine (2-chlorodeoxyadenosine)

21 January 2018

1 reference

Immune mechanisms of new therapeutic strategies in MS: teriflunomide

21 January 2018

1 reference

A placebo-controlled trial of oral cladribine for relapsing multiple sclerosis

21 January 2018

1 reference

Efficacy and safety of oral fumarate in patients with relapsing-remitting multiple sclerosis: a multicentre, randomised, double-blind, placebo-controlled phase IIb study

21 January 2018

1 reference

The Nrf2-antioxidant response element signaling pathway and its activation by oxidative stress

21 January 2018

1 reference

Placebo-controlled trial of oral laquinimod for multiple sclerosis

21 January 2018

1 reference

Suppression of experimental autoimmune neuritis by ABR-215062 is associated with altered Th1/Th2 balance and inhibited migration of inflammatory cells into the peripheral nerve tissue

21 January 2018

1 reference

Alemtuzumab vs. interferon beta-1a in early multiple sclerosis

21 January 2018

1 reference

Improvement in disability after alemtuzumab treatment of multiple sclerosis is associated with neuroprotective autoimmunity.

21 January 2018

1 reference

Interleukin-2/interleukin-2 antibody therapy induces target organ natural killer cells that inhibit central nervous system inflammation

21 January 2018

1 reference

Daclizumab in active relapsing multiple sclerosis (CHOICE study): a phase 2, randomised, double-blind, placebo-controlled, add-on trial with interferon beta

21 January 2018

1 reference

Long-term protection of central axons with phenytoin in monophasic and chronic-relapsing EAE.

21 January 2018

1 reference

Axonal protection using flecainide in experimental autoimmune encephalomyelitis.

21 January 2018

1 reference

Lamotrigine for neuroprotection in secondary progressive multiple sclerosis: a randomised, double-blind, placebo-controlled, parallel-group trial.

21 January 2018

1 reference

Sodium channels contribute to microglia/macrophage activation and function in EAE and MS.

21 January 2018

1 reference

Calcium channel blockers ameliorate disease in a mouse model of multiple sclerosis

21 January 2018

1 reference

Mechanisms of disease: sodium channels and neuroprotection in multiple sclerosis-current status

21 January 2018

1 reference

Erythropoietin crosses the blood-brain barrier to protect against experimental brain injury

21 January 2018

1 reference

The pleiotropic effects of erythropoietin in the central nervous system

21 January 2018

1 reference

Neuroprotective effects and intracellular signaling pathways of erythropoietin in a rat model of multiple sclerosis.

21 January 2018

1 reference

Patterns of cannabis use among patients with multiple sclerosis.

21 January 2018

1 reference

Emerging properties of cannabinoid medicines in management of multiple sclerosis

21 January 2018

1 reference

New perspectives in the studies on endocannabinoid and cannabis: abnormal behaviors associate with CB1 cannabinoid receptor and development of therapeutic application

21 January 2018

1 reference

Cannabinoids inhibit neurodegeneration in models of multiple sclerosis

21 January 2018

1 reference

New potent and selective inhibitors of anandamide reuptake with antispastic activity in a mouse model of multiple sclerosis

21 January 2018

1 reference

Are statins a treatment option for multiple sclerosis?

21 January 2018

1 reference

Simvastatin treatment in patients with relapsing-remitting multiple sclerosis receiving interferon beta 1a: a double-blind randomized controlled trial

21 January 2018

1 reference

Negative impact of statins on oligodendrocytes and myelin formation in vitro and in vivo.

21 January 2018

1 reference

A Phase II study of the safety and efficacy of teriflunomide in multiple sclerosis with relapses.

21 January 2018

1 reference

European/Canadian multicenter, double-blind, randomized, placebo-controlled study of the effects of glatiramer acetate on magnetic resonance imaging-measured disease activity and burden in patients with relapsing multiple sclerosis

21 January 2018

1 reference

Effect of early versus delayed interferon beta-1b treatment on disability after a first clinical event suggestive of multiple sclerosis: a 3-year follow-up analysis of the BENEFIT study

21 January 2018

1 reference

Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG)

21 January 2018

1 reference

Mitoxantrone in progressive multiple sclerosis: a placebo-controlled, double-blind, randomised, multicentre trial

21 January 2018

1 reference

A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis

21 January 2018

1 reference

B-cell depletion with rituximab in relapsing-remitting multiple sclerosis

21 January 2018

1 reference

Acid-sensing ion channel-1 contributes to axonal degeneration in autoimmune inflammation of the central nervous system.

21 January 2018

1 reference

Cannabinoids for treatment of spasticity and other symptoms related to multiple sclerosis (CAMS study): multicentre randomised placebo-controlled trial

21 January 2018

1 reference

Green tea epigallocatechin-3-gallate mediates T cellular NF-kappa B inhibition and exerts neuroprotection in autoimmune encephalomyelitis

21 January 2018

1 reference

Green tea epigallocatechin 3-gallate accumulates in mitochondria and displays a selective antiapoptotic effect against inducers of mitochondrial oxidative stress in neurons.

21 January 2018

1 reference

Tumor-necrosis-factor-related apoptosis-inducing-ligand (TRAIL)-mediated death of neurons in living human brain tissue is inhibited by flupirtine-maleate

21 January 2018

1 reference

Flupirtine as neuroprotective add-on therapy in autoimmune optic neuritis

21 January 2018

1 reference

The effect of the neuroprotective agent riluzole on MRI parameters in primary progressive multiple sclerosis: a pilot study

21 January 2018

1 reference

Topiramate protects against glutamate- and kainate-induced neurotoxicity in primary neuronal–astroglial cultures

21 January 2018

1 reference

Human brain-cell death induced by tumour-necrosis-factor-related apoptosis-inducing ligand (TRAIL)

21 January 2018

1 reference

Interferon beta-1a for brain tissue loss in patients at presentation with syndromes suggestive of multiple sclerosis: a randomised, double-blind, placebo-controlled trial

21 January 2018

1 reference

LINGO-1 antagonist promotes spinal cord remyelination and axonal integrity in MOG-induced experimental autoimmune encephalomyelitis

21 January 2018

1 reference

Exploring recombinant human erythropoietin in chronic progressive multiple sclerosis

21 January 2018

1 reference

Neurological disability correlates with spinal cord axonal loss and reduced N-acetyl aspartate in chronic multiple sclerosis patients

21 January 2018

1 reference

7 January 2021

New natural history of interferon-β-treated relapsing multiple sclerosis

1 reference

7 January 2021

Exacerbation of experimental autoimmune encephalomyelitis after withdrawal of phenytoin and carbamazepine

1 reference

7 January 2021

Multiple sclerosis☆Distribution of T cells, T cell subsets and Ia-positive macrophages in lesions of different ages

1 reference

7 January 2021

Effects of interferon-beta-1a on neuronal survival under autoimmune inflammatory conditions

1 reference

7 January 2021

Extended observations on MS patients treated with IM interferon-beta1a (Avonex): implications for modern MS trials and therapeutics

1 reference

7 January 2021

Direct suppression of CNS autoimmune inflammation via the cannabinoid receptor CB1 on neurons and CB2 on autoreactive T cells

1 reference

7 January 2021

Acute axonal injury in multiple sclerosis. Correlation with demyelination and inflammation

1 reference

7 January 2021

Acid-sensing ion channel 1 is involved in both axonal injury and demyelination in multiple sclerosis and its animal model

1 reference

7 January 2021

The internodal axon membrane: electrical excitability and continuous conduction in segmental demyelination

1 reference

7 January 2021

Less mortality but more relapses in experimental allergic encephalomyelitis in CD8-/- mice

1 reference

7 January 2021

CAMPATH-1H in multiple sclerosis

1 reference

7 January 2021

Histopathologic correlate of hypointense lesions on T1-weighted spin-echo MRI in multiple sclerosis

1 reference

7 January 2021

Use of the brain parenchymal fraction to measure whole brain atrophy in relapsing-remitting MS. Multiple Sclerosis Collaborative Research Group

1 reference

7 January 2021

Ionic mechanisms of anoxic injury in mammalian CNS white matter: role of Na+ channels and Na(+)-Ca2+ exchanger.

1 reference

7 January 2021

Conduction in segmentally demyelinated mammalian central axons

1 reference

7 January 2021

Cerebellar depolarization-induced suppression of inhibition is mediated by endogenous cannabinoids.

1 reference

7 January 2021

Oligodendrocytes promote neuronal survival and axonal length by distinct intracellular mechanisms: a novel role for oligodendrocyte-derived glial cell line-derived neurotrophic factor.

1 reference

7 January 2021